InsidersTradesSigma
Discover the full management transaction log of Insys Therapeutics, Inc., a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was disclosed on 9 February 2016 (Levée d'options). Among the most active insiders: MEYER STEVEN J. All data is free.
Analysts rate Insys Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Insys Therapeutics, Inc. is a pharmaceutical company focused on developing treatments, particularly for pain management. It is listed on the NASDAQ under the ticker symbol INSY.